Approval · Notice of Compliance 26970 · 2021
KYNMOBI: Notice of Compliance 26970
Issued November 4, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26970
- Date
- November 4, 2021
- Company
- Sunovion Pharmaceuticals Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in the specification for the drug product.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| KYNMOBI | Not yet assigned | — |
Medicinal ingredients
- APOMORPHINE HCL 10 MG per UNIT
- APOMORPHINE HCL 15 MG per UNIT
- APOMORPHINE HCL 20 MG per UNIT
- APOMORPHINE HCL 25 MG per UNIT
- APOMORPHINE HCL 30 MG per UNIT